cyrilzakka/clinical-trials huggingface dataset:
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management

Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.

The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on patients' perceptions of thromboprophylaxis, in order to enhance clinical practice and establish a foundation of evidence for managing patients with VTE.


Eligibility Criteria:
Inclusion Criteria:

* Inpatients ≥18 years of age at admission;
* Previous or current definitive diagnosis of DVT and/or PE by imaging, or at high risk of VTE at discharge: Padua score ≥4 for medical patients and Caprini score ≥5 for surgical patients.
* Signed informed consent

Exclusion Criteria:

* Mental disorder or combination of other serious diseases leading to incapacity for independent living;
* Inability to use smartphones, computer tablets and other smart devices;
* Being pregnant or breastfeeding;
* Have participated in similar trials or are undergoing other clinical trials.
Multiple Interactive With Nutrition and Exercise Strategies in Frailty Cancer Patients

Due to the changes in lifestyle caused by the COVID-19, it is a priority to provide multi-interactive digital platforms and social media for nutrition and exercise programs for cancer patients. A two-year serial program uses mixed study methods of longitudinal combined experimental study. We will investigate cancer frailty's current situation and track the frailty trends after cancer patients received different treatments. We will also invite experts to develop multi-interactive digital platforms of nutrition and performance-based tailored circuit training programs according to the cancer frailty survey. We will recruit 20-85 years of newly diagnosed or first-time recurrence cancer patients and stratified randomization assigned to evaluate nutrition and physical exercise intervention effectiveness. The measure indicators were treatment-related adverse events, nutritional status, frailty status, survival rate, and life quality.


Eligibility Criteria:
Inclusion Criteria:

* Aged from 20-85 years with histological confirmation malignancy.
* Requiring treatment by surgery, chemotherapy, hormonotherapy, radiotherapy, or targeted therapy with a curative intention as estimated by oncologists.
* First diagnosed or recurrence of head and neck cancer, esophageal cancer, colon/rectum cancer, lung cancer, AML, ALL, lymphoma, multiple myeloma.

Exclusion Criteria:

* Non-head and neck cancer, esophageal cancer, colon/rectum cancer, lung cancer, AML, ALL, lymphoma, multiple myeloma with first diagnosis or recurrence patients.
* Eastern Cooperative Oncology Group test score\>2.
* Serious psychiatric or cognitive problems, and functional disability leading to a total inability to walk.
Transitional Ankle Fracture Management Using a New Joystick Technique

To investigate the feasibility and short-term clinical efficacy of the arthrography-assisted joystick technique for the treatment of adolescent transitional ankle fracture.

Adolescent transitional ankle fracture who were treated with the arthrography-assisted joystick technology.

Eligibility Criteria:
Inclusion Criteria:

1. X-ray or computed tomography (CT) diagnosis of adolescent transitional ankle fracture.
2. After manual reduction, the displacement of both ends of the epiphyseal plate or articular surface fracture in any direction was still \> 2 mm; the arthrography-assisted joystick technique was used for treatment.

Exclusion Criteria:

1. Bilateral fracture.
2. In association with epiphyseal dysplasia and neuromuscular disease.
From Research to Practice - Lipid Management for Low HDL-Cholesterol

The overall purpose of this project is to improve the clinical outcomes of veterans with ischemic heart disease (IHD) through implementation of evidence-based lipid management, with a particular focus on veterans whose primary lipid abnormality is a low level of HDL-cholesterol (the �good� cholesterol).

Background:

The overall purpose of this project is to improve the clinical outcomes of veterans with ischemic heart disease (IHD) through implementation of evidence-based lipid management, with a particular focus on veterans whose primary lipid abnormality is a low level of HDL-cholesterol (the �good� cholesterol).

Objectives:

The major objectives are 1. to determine whether a multifaceted intervention results in improved guideline-concordant lipid management for patients with low HDL-cholesterol; and 2. to test the relative effectiveness of three different reminder systems on physician prescribing behavior.

Methods:

The primary care clinic at each of the six VISN 13 facilities will serve as intervention sites. Within those sites we will randomize providers to one of three reminder systems. Control sites will consist of twelve other facilities matched to the intervention sites on the basis of facility characteristics. We will use a modified �pre-post� nested cohort design that allows us to evaluate the effect of the intervention controlling for secular trends. Target patients will be identified based on the following: 1. an IHD diagnosis within the past 5 years; 2. regular follow-up in a primary care clinic; 3. most recent LDL-cholesterol \< 130 mg/dl and HDL-cholesterol \< 40 mg/dl; 4. No lipid therapy within prior 6 months. The intervention will consist of: a. an on-site interactive educational workshop for providers; b. reminders (either patient-directed mailed reminders, computer-chart reminders at the time of visit, or automatic consults); c. opinion leader recruitment and �activation�. The primary outcome is proportion of target patients receiving guideline-concordant therapy. For objective 1, the outcome will be compared between intervention and control sites. For objective 2, the outcome will be compared between the three groups randomized to the different reminder systems. In addition, providers will be surveyed with a written questionnaire to determine their reaction to the educational workshop and the different reminder systems.

Status:

Intervention and data collection are completed. Data analysis is being undertaken, final report will soon follow.

Eligibility Criteria:
Inclusion Criteria:

Subjects are primary care providers from participating VISN sites. Patients whose medical records are utilized are selected via an algorithm.

Exclusion Criteria:
Feasibility and Effectiveness of Concurrent Exercise Training on Frail Older Adults Living in Nursing Homes

The present study is a crossover randomized controlled trial that aims to investigate the effects of concurrent exercise training over usual care on physical performance, muscle strength, and myokines concentrations in frail older adults living in nursing homes.The main questions it aims to answer is: Can a 12-week exercise intervention provide beneficial effects on physical performance, muscle strength and myokines among the most frail participants? Researchers will compare this intervention to usual care. Nursing homes (comprising participants) will be randomly assigned to a sequence of interventions (AB or BA), being A -exercise and B usual care. Participants will be assessed before and after each intervention.

The present study is a crossover randomized controlled trial that aims to investigate the effectiveness of a concurrent exercise training over usual care on physical performance, muscle strength, and myokines concentrations in frail older adults living in nursing homes. Nursing homes will be randomly assigned to receive a sequence of interventions (AB or BA), being A -exercise and B usual care. Participants will receive a 12-weeks of either exercise intervention or usual care. A 4-week washout period will be conducted between interventions. Participants will assessed before and after each intervention.

Eligibility Criteria:
Inclusion Criteria:

* Classified as frail according to the Fried criteria (e.g., frailty phenotype ≥ 3 criteria);
* Not having participated in any exercise intervention for the last 3 months;
* Being able to ambulate (with/without assistance).

Exclusion Criteria:

* Any contraindication that could affect physical exercise performance or testing procedures, including terminal illness, uncontrolled disease or other unstable medical condition;
* Bone fracture in the past three months;
* having a short physical performance battery score (SPPB) \< 3.
Evaluation of the Abutment Type Following Oral Implants in Terms of the Surrounding Bone Height

Compare two different types of abutments (molded abutments and computer-designed 3D printed abutments) in terms of the amount of bone loss, and depth of periodontal pockets around the implant during different periods.

In the past few years, the number of research conducted on the designs of abutments and materials has increased. Often, the restoration is done over the implant using standard abutments that the implant company prefabricated, but due to the problems facing the dentist from the occurrence of bone absorption, an increase in the depth of the pocket after restoration, other types of abutment design methods have been introduced as needed (molded abutment made by lost wax technique and computer-designed abutment made using a 3D laser printer), those customised abutments were made special for each patient depending on their conditions.

Eligibility Criteria:
Inclusion Criteria:

* The patient's age is greater than 20 years and younger than 50
* Good oral health
* Absence of systemic diseases that may affect the healing of surrounding tissues, such as diabetes.

Exclusion Criteria:

* The presence of non-functional habits such as stridor
* Acute or acute periodontitis, previous loss of implants
* Poor general health conditions
* Previous radiotherapy in the head and neck area
* Mental incompetence
* Orthodontic treatment
Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS

The investigators' study titled "PROTONS-RPS: a Phase II non-Randomized Open-label single-arm Trial Of Neoadjuvant Short-course hypofractionated proton beam therapy for non-metastatic RetroPeritoneal Sarcoma" is a phase II trial evaluating the safety and efficacy of hypofractionated proton beam therapy (H-PBT) in the neoadjuvant (NA) setting for patients with non-metastatic retroperitoneal sarcoma (RPS) planned for surgical resection. This trial will include adult patients with resectable RPS.

The investigators' primary outcome is overall complication rate after treatment with NA H-PBT and surgical resection based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.2 Secondary objectives include evaluating the acute toxicity of H-PBT prior to surgical resection, rate of progression between diagnosis and definitive resection, early post-operative complication rate after resection of RPS in patients who received NA H-PBT, and local recurrence-free survival at 1 and 2 years. A priori subset analyses will be conducted for patients with well-differentiated and dedifferentiated liposarcoma.

The investigators plan to accrue a minimum of 44 patients to evaluate the investigators' primary outcome. Treatment will be 5 doses of H-PBT including a simultaneous integrated boost to at-risk margins followed by surgical resection after 4-6 weeks. Patients will be followed in the post-operative setting according to standard of care surveillance for RPS.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (≥18 years of age)
* Patients with primary non-recurrent retroperitoneal sarcoma
* Calculated creatinine clearance ≥50 mL/min and functional contralateral kidney based on nuclear medicine renal scan
* Normal bone marrow function (WBC ≥ 4 x109 /L)
* Eastern Cooperative Oncology Group status ≤ 2
* Cardiac function ≤ New York Heart Association class II
* Proton beam therapy approved by insurance (including Medicare/Medicaid)

Exclusion Criteria:

* Evidence of metastatic disease on staging CT of chest/abdomen/pelvis
* History of abdominal or pelvic radiation therapy
* Inability to tolerate supine position for duration of PBT simulation or treatment
* Tumor originating from gastrointestinal or gynecologic organs
* Specific sarcoma histologies including osteosarcoma, desmoid tumors, chondrosarcoma arising from vertebrae or pelvic bones, embryonal rhabdomyosarcoma
* Tumor extending into femoral or obturator canal
* History of systemic lupus erythematosus or ulcerative colitis
* Genetic syndrome with radiation-associated tumorigenicity (i.e.: Li-Fraumeni)
* Presence of clinically significant ascites
* Co-existing malignancy or treated malignancy in the last 2 years expected to limit life expectancy; does not include completely resected cutaneous basal cell carcinoma, squamous cell carcinoma, in situ breast or cervical malignancies, or other pathologies at the discretion of the investigators.
Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective Study

Knowing the tumor size before operation is of great significance to the choice of treatment methods of surgeons and the prognosis of patients. In this study, two commonly used imaging methods( CE-MRI/CEUS) were selected to measure and compare the tumor size before operation, in order to determine which measurement method is more accurate.

A total of 194 patients who met the inclusion criteria from January 2019 through May 2024 were included. Taken pathological results as the gold standard, Paired T-test and Bland-Altman analisis were conducted to assess the correlation and mean absolute error between the measured tumor sizes obtained from CE-MRI/CEUS and pathological results.

Eligibility Criteria:
Inclusion Criteria:

1. had no anti-HCC therapy before imaging examinations.
2. at least had one examination of Gd-EOB-DTPA-enhanced MRI and CEUS 2 weeks before surgery and confirmed as one single HCC.
3. If the patient had both imaging tests, the time interval between two examinations was less than 1 weeks.
4. both radiological and pathological results recorded the maximum tumor diameter.

Exclusion Criteria:

1. had anti-HCC therapy before imaging examinations.
2. had no examination of Gd-EOB-DTPA-enhanced MRI or CEUS 2 weeks before surgery .
3. had no radiological or pathological results recorded the maximum tumor diameter.
Feasibility Trial of the DC Devices Interatrial Septal Device (IASD) System

The purpose of this study is to evaluate the safety and potential benefits of the interatrial septal defect (IASD) System in patients with heart failure with preserved ejection fraction.

The study was a multi-center, non-randomized feasibility evaluation of the IASD System at three centers in three countries (Denmark, Australia, and Czech Republic). Relevant ethics committee and competent authority approvals were obtained. The study was conducted in accordance with the Declaration of Helsinki. The protocol required the treatment of a minimum of 5 patients, and allowed up to twenty patients to be enrolled.

The primary objective of the trial was to evaluate the safety and potential benefits of the IASD Device System in the treatment of patients with symptomatic heart failure with preserved ejection fraction, despite optimal medical management.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of HFpEF
* Ejection Fraction of at least 45%
* Imaging and hemodynamic evidence of HFpEF
* History of exercise intolerance
* Symptomatic despite optimal medical management
* Signed study specific informed consent

Exclusion Criteria:

* History of thromboembolic events
* Significant structural heart disease or coronary artery disease
* Contraindicated to study required medication
* Right ventricular dysfunction
* History of greater than mild restrictive or obstructive lung disease
* Life expectancy less than one year for non-cardiovascular reasons
* Known or suspected allergy to implant material
* Fertile women
Feasibility and Outcomes of Older Patients Hospitalization

Hospitalization is a traumatic event for the patient and his family at any age nevertheless in the older age. One of its consequences is the difficulty to resume previous activity of daily living especially in older (over 75 years) patients. Sub acute completes the acute phase of the hospitalization and its main purpose is to improve the patient's functional status and quality of life. There are not enough clinical trails to proof this assumption. The purpose of our study is to compare the outcome of acute and sub-acute hospitalization programs by a randomized controlled prospective intervention study. Outcome measures will comprise activity of daily living, functional status, re-hospitalization and utilization of medical services following the hospitalization.Study hypothesis is that sub-acute hospitalization will improve outcomes and will cost less.


Eligibility Criteria:
Inclusion Criteria:

* Age over 65
* Hemodynamic, nutritional and respiratory stability
* eligibility for sub- acute hospitalization

Exclusion Criteria:

* Oncological active disease
* uncorrectable hypoxemia (oxygen saturation 90%),
* suspected myocardial ischemia
* presence of an acute illness, other than the target illness
Intubation Tube Applications on Voice Performance in Early Postoperative Period

Changes in voice performance in the postoperative period due to trauma suffered during endotracheal intubation or edema occurring in the postoperative period are often observed. The present study aimed to evaluate the effect of different types of intubation tube applications on voice performance in the early postoperative period using objective and subjective voice analysis methods.

A total of 88 patients who underwent endotracheal intubation either using a cuffed endotracheal (n = 44) or spiral-embedded cuffed endotracheal (n = 44) tube were included in this study. An endotracheal tube of 7.5 mm was used for female patients and that of 8 mm was used for male patients. A preoperative acoustic voice analysis was performed, and fundamental frequency (F0), jitter%, and shimmer% values were recorded. In addition, voice handicap index-30 (VHI-30) questionnaire was completed by the patients for subjective evaluation. The same procedure was repeated in the first 48 hours postoperatively. The preoperative and postoperative data were statistically compared. In addition, the effect of the type of endotracheal intubation tube on acoustic voice analysis parameters and VHI-30 scores was statistically evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18-80 years
* Conforming to the ASA I-II class according to the classification of the American Society of -Anesthesiologists (ASA)
* who were scheduled to undergo surgery that will not last more than 120 minutes

Exclusion Criteria:

* Patients with a lung disease
* Having obesity (BMI \>35 kg.m-2)
* Pregnant patients
* Gastroesophageal reflux
* Suspected of having difficult airway (mouth opening \<2.5 cm, Mallampati score \>2, sternomental distance \<12.5 cm, thyromental distance \<6 cm, neck circumference \>40 cm)
* A high risk of aspiration pneumonia
* Using inhaled steroids
Cardiovascular Impact of Obstructive Sleep Apnea Treatment in Normotensive Patients

Recent evidences suggest that obstructive sleep apnea (OSA) can contribute to cardiovascular disease even in the absence of hypertension. However, there are few data regarding the impact of OSA on the preHypertension and Masked Hypertension in apparently normotensive patients with OSA as well as the impact of treatment with continuous positive airway pressure.


Eligibility Criteria:
Inclusion Criteria:

* Severe OSA patients

Exclusion Criteria:

* Smoking
* Sustained Hypertension
* Heart failure
* Diabetes
* Renal diseases
* Under use of any medication
* Under treatment for OSA
Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction

The aim of the study is to investigate the effect of dapagliflozin or placebo on acetylcholine (Ach)- or nitroglycerin (GTN)-induced vasodilation of the forearm resistance vasculature, as determined by FBF measurement before and 10 minutes after 20 minutes of forearm ischemia.

The aim is to test the effect of dapagliflozin or placebo on ACh-induced vasodilatation of the forearm resistance vasculature as assessed by FBF measurement before and 10 min after a 20 min forearm ischemia as well as after a 14 day treatment period. The area under the dose-effect curve (AUC) of different ACh doses will be calculated and compared between treatment groups (dapagliflozin vs. placebo) and different time points (pre-ischemia vs. post-ischemia). FBF measurements will be made in response to increasing intra-arterial doses of ACh (25, 50, 100 nmol/min) to assess endothelial function or GTN (4, 8, 16 nmol/min) to test vascular smooth muscle vasodilator function.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male subjects; 18 - 40 years of age
* Body mass index between 18 and 27 kg/m2
* Written informed consent
* Normal findings in medical history
* Non-smoking

Exclusion Criteria:

* Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration
* History of occlusive vascular diseases
* History of vascular anomalies
* History of coagulation disorders
* History of diabetes mellitus (Type 1\&2) or pre-diabetes (i.e. HbA1c ≥ 5,7 %)
* History of kidney disease
* History of ketoacidosis
* Impaired liver function (AST, ALT, gGT, bilirubin \>3 x ULN)
* Impaired renal function (serum creatinine \> 1.3 mg/dl)
* Any other relevant deviation from the normal range in clinical chemistry, haematology or urine analysis
* HIV-1/2-Ab, HbsAg or HCV-Ab positive serology
* Systolic blood pressure above 145 mmHg, diastolic blood pressure above 95 mmHg
* Known allergy against any test agent under study and/or lactose intolerance
* Regular daily consumption of more than on litre of xanthine-containing beverages or more than 40g alcohol
* Participation in another clinical trial during the preceding 3 weeks